|
EP0961830A1
(en)
*
|
1997-01-29 |
1999-12-08 |
Neurosearch A/S |
EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
|
|
AU2001290984A1
(en)
*
|
2000-09-18 |
2002-04-02 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
EP1624067A3
(en)
*
|
2000-09-18 |
2006-03-15 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
JP4500044B2
(ja)
*
|
2001-07-04 |
2010-07-14 |
クロマジェニックス ビー．ブイ． |
遺伝子転写を調節する特性を含むｄｎａ配列及びそのようなｄｎａ配列を検出し且つ使用するための方法
|
|
DE10256083A1
(de)
*
|
2002-11-29 |
2004-08-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
|
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
|
US7344886B2
(en)
|
2002-11-29 |
2008-03-18 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
|
|
US8669109B2
(en)
|
2003-08-19 |
2014-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methods of producing proteins in Chinese hamster ovary (CHO) cells
|
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
|
US20050101017A1
(en)
*
|
2003-11-10 |
2005-05-12 |
Wojtek Auerbach |
Method of improving gene targeting using a ubiquitin promoter
|
|
GB0509965D0
(en)
*
|
2005-05-17 |
2005-06-22 |
Ml Lab Plc |
Improved expression elements
|
|
UA92913C2
(ru)
*
|
2005-06-20 |
2010-12-27 |
Кадила Хелткере Лимитед |
Экспрессионный вектор и способы продуцирования высоких уровней белков
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
US20080124760A1
(en)
*
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
|
BR112014010198B1
(pt)
|
2011-10-28 |
2022-12-06 |
Prothena Biosciences Limited |
Anticorpos humanizados que reconhecem alfa-sinucleína
|
|
DK2807188T3
(da)
|
2012-01-27 |
2019-10-07 |
Prothena Biosciences Ltd |
Humaniserede antistoffer, der genkender alpha-synuclein
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
WO2014102101A1
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Novel intron sequences
|
|
EP2938726B1
(en)
|
2012-12-31 |
2017-09-27 |
Boehringer Ingelheim International GmbH |
Heterologous intron within a signal peptide
|
|
EP3689904A1
(en)
|
2013-03-13 |
2020-08-05 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US9989540B2
(en)
|
2013-05-10 |
2018-06-05 |
The Regents Of The University Of California |
Diagnostic and monitoring system for Huntington's disease
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
WO2015004632A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize iapp
|
|
US9951131B2
(en)
|
2013-07-12 |
2018-04-24 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
US11191832B2
(en)
|
2013-11-19 |
2021-12-07 |
Prothena Biosciences Limited |
Monitoring immunotherapy of Lewy body disease from constipation symptoms
|
|
EP3666287A1
(en)
|
2013-12-31 |
2020-06-17 |
ProteoNic Biotechnology IP B.V. |
Construct and sequence for enhanced gene expression
|
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
|
|
CA2938931A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg1-3
|
|
JP2017514458A
(ja)
|
2014-03-12 |
2017-06-08 |
プロセナ バイオサイエンシーズ リミテッド |
Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
|
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
|
WO2015155694A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
PH12017501089B1
(en)
|
2014-12-10 |
2022-06-22 |
Opko Biologics Ltd |
Methods of producing long acting ctp-modified growth hormone polypeptides
|
|
TWI781507B
(zh)
|
2015-01-28 |
2022-10-21 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI718122B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI711631B
(zh)
|
2015-01-28 |
2020-12-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
US10881102B2
(en)
|
2015-05-18 |
2021-01-05 |
Zymtronix, Llc |
Magnetically immobilized microbiocidal enzymes
|
|
CN108140848B
(zh)
|
2015-07-15 |
2022-02-01 |
齐姆特罗尼克斯公司 |
自动化生物纳米催化剂生产
|
|
WO2017046776A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
JP7481726B2
(ja)
|
2016-05-02 |
2024-05-13 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
KR102750101B1
(ko)
|
2016-05-02 |
2025-01-03 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
|
WO2017191559A1
(en)
|
2016-05-02 |
2017-11-09 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
JP7076711B2
(ja)
|
2016-07-02 |
2022-05-30 |
プロセナ バイオサイエンシーズ リミテッド |
抗トランスサイレチン抗体
|
|
EP3478716A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
JP7016470B2
(ja)
|
2016-07-02 |
2022-02-07 |
プロセナ バイオサイエンシーズ リミテッド |
抗トランスサイレチン抗体
|
|
KR102618424B1
(ko)
|
2016-07-11 |
2023-12-26 |
옵코 바이오로직스 리미티드 |
지속성 응고 인자 vii 및 그 제조 방법
|
|
CA3031802A1
(en)
|
2016-08-13 |
2018-02-22 |
Zymtronix Catalytic Systems, Inc. |
Magnetically immobilized biocidal enzymes and biocidal chemicals
|
|
EP3568464A1
(en)
|
2017-01-13 |
2019-11-20 |
The Regents of The University of California |
Immunoengineered pluripotent cells
|
|
PE20200695A1
(es)
|
2017-05-02 |
2020-06-16 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
WO2019064053A1
(en)
|
2017-09-28 |
2019-04-04 |
Prothena Biosciences Limited |
DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
|
MX2020003043A
(es)
|
2017-10-06 |
2020-10-05 |
Prothena Biosciences Ltd |
Métodos para detectar transtiretina.
|
|
PH12020550694A1
(en)
|
2017-11-29 |
2021-04-12 |
Prothena Biosciences Ltd |
Lyophilized formulation of a monoclonal antibody against transthyretin
|
|
JP7453961B2
(ja)
|
2018-09-05 |
2024-03-21 |
ザイムトロニクス キャタリティック システムズ インコーポレイテッド |
磁気骨格上の固定化酸素及びミクロソーム
|
|
SG11202104549TA
(en)
|
2018-11-08 |
2021-05-28 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
UA128431C2
(uk)
|
2018-11-26 |
2024-07-10 |
Форті Севен, Інк. |
ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
|
|
PE20212324A1
(es)
|
2019-03-03 |
2021-12-14 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
EP3966316A4
(en)
|
2019-05-10 |
2023-01-25 |
The Regents of The University of California |
MODIFIED PLURIPOTENT CELLS
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
AU2020307550A1
(en)
|
2019-06-26 |
2022-02-03 |
The Regents Of The University Of California |
SIRPalpha-silenced natural killer (NK) cells
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ２４発現細胞およびそれらの用途
|
|
WO2021146222A1
(en)
|
2020-01-13 |
2021-07-22 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
WO2021146471A2
(en)
|
2020-01-15 |
2021-07-22 |
The Regents Of The University Of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
TW202140784A
(zh)
|
2020-01-17 |
2021-11-01 |
美商薩那生物科技公司 |
用於調節基因表現的安全開關
|
|
CN115768446A
(zh)
|
2020-03-25 |
2023-03-07 |
萨那生物技术股份有限公司 |
用于治疗神经病症和疾患的低免疫原性神经细胞
|
|
CN116249717A
(zh)
|
2020-06-24 |
2023-06-09 |
普罗塞纳生物科学有限公司 |
识别分拣蛋白的抗体
|
|
EP4196568A1
(en)
|
2020-08-13 |
2023-06-21 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
US11965022B2
(en)
|
2020-12-31 |
2024-04-23 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating CAR-T activity
|
|
WO2022246293A1
(en)
|
2021-05-19 |
2022-11-24 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
JP2024534771A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
MX2024001208A
(es)
|
2021-08-11 |
2024-04-22 |
Sana Biotechnology Inc |
Celulas primarias geneticamente modificadas para terapia celular alogenica.
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
TW202440929A
(zh)
|
2022-12-14 |
2024-10-16 |
加拿大商普羅維登斯治療控股公司 |
用於感染性疾病的組合物和方法
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025059515A2
(en)
|
2023-09-15 |
2025-03-20 |
Prothena Biosciences Limited |
Cell penetrating agents and uses thereof
|
|
TW202530253A
(zh)
|
2023-09-15 |
2025-08-01 |
愛爾蘭商普羅希那生物科學有限公司 |
抗ｔｄｐ－４３抗體及其用途
|
|
TW202528337A
(zh)
|
2023-09-15 |
2025-07-16 |
愛爾蘭商普羅希那平台科技有限公司 |
包括細胞穿透藥劑之方法、組合物、及套組
|
|
WO2025059487A2
(en)
|
2023-09-15 |
2025-03-20 |
Othair Prothena Limited |
Cell penetrating agents and uses thereof
|
|
WO2025166633A2
(en)
|
2024-02-07 |
2025-08-14 |
Westlake Genetech. Ltd. |
Split gene editing systems and uses thereof
|